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Abstract 23 
The rising antimicrobial resistance contributes to 25000 annual deaths in Europe. This threat 24 
to the public health can only be tackled if novel antimicrobials are developed, combined with a 25 
more precise use of the currently available antibiotics through the implementation of fast, 26 
specific, diagnostic methods. Nucleic acid mimics (NAMs) that are able to hybridize 27 
intracellular bacterial RNA have the potential to become such a new class of antimicrobials and 28 
additionally could serve as specific detection probes. However, an essential requirement is that 29 
these NAMs should be delivered into the bacterial cytoplasm, which is a particular challenge 30 
given the fact that they are charged macromolecules.  31 
We consider these delivery challenges in relation to the gastric pathogen Helicobacter pylori, 32 
the most frequent chronic infection worldwide. In particular, we evaluate if cationic fusogenic 33 
liposomes are suitable carriers to deliver NAMs across the gastric mucus barrier and the 34 
bacterial envelope. Our study shows that DOTAP-DOPE liposomes post-PEGylated with 35 
DSPE-PEG (DSPE Lpx) can indeed successfully deliver NAMs into Helicobacter pylori, while 36 
offering protection to the NAMs from binding and inactivation in gastric mucus isolated from 37 
pigs. DSPE Lpx thus offer exciting new possibilities for in vivo diagnosis and treatment of 38 
Helicobacter pylori infections.   39 
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 43 
Introduction 44 
Infectious diseases are responsible for 14 million annual deaths, representing around 90% of 45 
the health problems worldwide [1]. Infections that could be treated for decades by classic 46 
antibiotics have become a serious threat to human health due to the advent of antimicrobial 47 
resistance [1, 2]. However, nucleic acid mimics (NAMs) designed to specifically hybridize in 48 
situ with complementary bacterial RNA, hold promise both for treatment and diagnosis of 49 
infections. Contrary to traditional oligonucleotides, NAMs are composed of modified DNA or 50 
RNA sugars that make them resistant to endonuclease degradation and improve their affinity 51 
towards RNA targets [3-6].  52 
NAMs can be designed to act as antisense antimicrobials, by hybridizing and consequently 53 
inhibiting the expression of selected genes [7-9]. These can be essential bacterial genes, thus 54 
preventing bacteria growth, or genes involved in the resistance to antibiotics, thus restoring 55 
bacteria susceptibility to antibiotics. This strategy provides a potentially endless source of 56 
active antibacterials. Even if the bacterial target undergoes a point mutation, which is the most 57 
common form of resistance to antibiotics [10], the oligonucleotide can be easily redesigned to 58 
become effective again.  59 
In addition, NAMs conjugated with a contrast agent could serve as detection probes for rapid 60 
and comprehensive in vivo diagnosis. They could detect not only the presence of specific 61 
bacteria, but also the presence of bacterial genes responsible for resistance to antibiotics, so that 62 
an effective antibacterial drug can be prescribed in time [3, 11-14]. Compared to the current 63 
diagnostic techniques, labelled NAMs have the potential to overcome the traditional time-64 
consuming culture methods as well as the need of bacteria isolation and extraction of target 65 
genetic material associated with other molecular methods, like PCR [2, 12, 15].  66 
In addition to their value for therapy and clinical diagnosis, the opportunity to directly 67 
localize bacteria in vivo is also of interest for research purposes. The host-microbial and 68 
microbial-microbial interactions, which can have an impact on the immune system and disease 69 
state, are mostly missed by the lack of a technique to visualize live bacteria within their in vivo 70 
environment [13, 16, 17]. NAMs hold the potential to respond to this need. 71 
For NAMs to fulfil their promise as a flexible platform for diagnosis and treatment of 72 
bacterial infections, they should be safely delivered across biological barriers in the body. 73 
Mucus in the gastrointestinal, respiratory, reproductive and urinary tracts presents a first barrier 74 
for NAMs [18-20]. Mucus is a highly complex and viscoelastic network able to bind foreign 75 
entities (through electrostatic, hydrophobic or hydrogen bonds) and/or sterically obstruct 76 
particles which are larger than the size of the pores in mucus [19, 21, 22]. Therefore, NAMs 77 
need to be able to pass through mucus to reach the target bacteria [23]. Importantly, they should 78 
do so without losing their activity. Indeed, we have recently shown that interactions with gastric 79 
mucus can significantly compromise the ability of NAMs to hybridize with Helicobacter pylori 80 
(H. pylori) [24]. 81 
Apart from crossing the mucus layer, it is pivotal that the NAMs are delivered into the 82 
cytoplasm of bacterial cells. Unlike eukaryotic cells, bacteria possess a multi-layered cell 83 
envelope which is recognized as a challenging barrier for oligonucleotide penetration [8, 25]. 84 
Strategies to permeabilize the bacterial envelope in vitro include electroporation, enzymatic 85 
(e.g. lysozyme) or chemical (e.g. ethanol) treatment. None of those are, however, easily 86 
transferable to in vivo. While cell-penetrating peptides (CPPs) conjugated to antisense NAMs 87 
may be promising [14, 26-30], conventional CPPs induce cytotoxicity and possess low in vivo 88 
stability [31-34]. In addition, bacterial resistance to CPP-mediated penetration has been 89 
reported [32].  90 
In this work we have considered both delivery challenges, i.e. crossing mucus and the cell 91 
envelope, in the context of gastric H. pylori infection (Figure 1a), which is the most frequently 92 
occurring chronic bacterial infection worldwide [35]. H. pylori reside within the gastric mucus 93 
layer as well as in close proximity with the epithelial cells underlying the gastric mucus layer 94 
[36]. Here we investigated if fusogenic stealth liposomes are suitable nanocarriers for NAMs 95 
to target H. pylori infections. Liposomes have been extensively studied to deliver nucleic acids 96 
into eukaryotic cells [37]. Until now their application to treat bacterial infections is almost 97 
exclusively limited to the delivery of traditional small molecule antibiotics [38-41]. So far, only 98 
two papers report on the use of liposomes to deliver phosphorothioate DNA in Escherichia coli 99 
and in Staphylococcus aureus [42, 43]. In spite of its promise it shows that liposomal delivery 100 
of nucleic acids into bacteria is a virtually unexplored area.  101 
In the current study we use fusogenic cationic liposomes, made from the lipids DOTAP and 102 
DOPE, which are well-characterized carriers for nucleic acids in eukaryotic cells [44-46]. We 103 
reasoned that DOTAP-DOPE liposomes may be of interest for delivery in gram negative 104 
bacteria due to the presence of the fusogenic lipid DOPE which may promote fusion of the 105 
liposomes with the cell envelope, thus delivering its content into the cell’s cytoplasm [47, 48]. 106 
Based on our previous work, locked nucleic acids (LNA) and 2’-OMethyl 107 
RNA (2’OMe), with either phosphodiester (PO) or phosphorothioate (PS) as backbone linkages 108 
(Figure 1b), were used as NAMs to hybridize to H. pylori rRNA [24, 49]. Electrostatic 109 
complexes between (anionic) NAMs and (cationic) DOTAP-DOPE liposomes were formed, 110 
which were further modified by post-insertion of PEG-lipids with the aim to improve the 111 
stability and mobility of the complexes in the harsh gastrointestinal environment [50, 51]. We 112 
tested two PEGylation strategies: DSPE-PEG that stably incorporates into liposomes and Cer-113 
PEG that can diffuse out of the liposomes over time [52, 53]. First, we evaluated if those 114 
PEGylated lipoplexes have good diffusional mobility in gastric mucus isolated from pigs, being 115 
a clear prerequisite to be able to reach the bacteria dispersed in the mucus. Next, it was 116 
investigated whether the PEGylated lipoplexes could deliver NAMs into H. pylori in suspension 117 
by fluorescence in situ hybridization (FISH). Finally, we assessed if the PEGylated lipoplexes 118 
could still successfully deliver functional NAMs in H. pylori in the presence of gastric mucus.  119 
 120 
Figure 1. (a) Illustration of the study concept: representation of liposomal delivery of NAMs 121 
across the gastric mucus to target H. pylori. (b) Monomers of the NAMs used in FISH, 122 
compared to RNA. (c) Procedure followed for the collection of mucus from the stomach of 123 
pigs. (Adapted from [24] and  [49]). 124 
 125 
 126 
Materials and Methods  127 
 128 
Materials 129 
(2,3-Dioleoyloxy-propyl)-trimethylammonium-chloride (DOTAP), 1,2-dioleoyl-sn-130 
glycero-3-phosphoethanolamine (DOPE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-131 
N-(methoxy(polyethyleneglycol)-2000) (DSPE-PEG), N-octanoyl-sphingosine-1- 132 
succinyl[methoxy(polyethylene glycol)2000] (CerC8-PEG) and DOPE-133 
LissamineRhodamineB were purchased from Avanti Polar Lipids (Alabaster, AL). Yellow-134 
green (505/515) fluorescent carboxylate-modified polystyrene FluoSpheres® of 40, 100, 200 135 
and 500 nm of diameter were purchased from Invitrogen Molecular Probes (Eugene, OR). N-136 
(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-137 
Hydroxysulfosuccinimide sodium salt (sulfo-NHS) were acquired from Sigma-Aldrich 138 
(Bornem, Belgium) and 2 kDa methoxy-polyethylene glycol-amine (mPEGa) from Creative 139 
PEGWorks (Winston Salem, USA). Chloroform, 4-(2-hydroxyethyl)-1-140 
piperazineethanesulfonic acid (HEPES), 2-Amino-2-(hydroxymethyl)-1,3-propanediol 141 
hydrochloride (Tris-HCl), sodium chloride (NACl) and triton X-100 were purchased from 142 
Sigma-Aldrich (Bornem, Belgium). Paraformaldehyde was acquired from Fluka – Sigma-143 
Aldrich, (Bornem, Belgium). Urea was purchased from Vel – VWR (Haasrode, Belgium). 144 
Pepsin (from porcine gastric mucosa) was purchased from Merck Millipore (Madrid, Spain). 145 
Trypticase soy agar plates supplemented with 2% (v/v) sheep blood were purchased from 146 
Becton Dickinson GmbH (Erembodegem, Belgium). CampyGen sachets to generate 147 
microaerobic conditions were acquired from Oxoid – Thermo Scientific (Waltham, MA, USA).  148 
 149 
Collection of porcine gastric mucus 150 
Mucus scraped from the stomach of pigs was used in this study, as its bio-relevance is 151 
markedly higher than mucus solutions prepared from commercial mucins [54, 55]. Also, pigs 152 
have a gastric physiology similar to humans, making them representative animal models for 153 
Helicobacter infection studies [56, 57]. 154 
Stomachs were collected from a local slaughterhouse, opened at the greater curvature and 155 
gently rinsed with tap water to remove most of the food debris [58]. The mucus, loosely bound 156 
and adherent, was then gently scrapped off with a glass slide, aliquoted and stored at -80°C. 157 
Mucus from three different pigs was included in each experiment. 158 
 159 
NAMs synthesis 160 
Two oligonucleotides complementary to a sequence of the H. pylori 16S rRNA gene, were 161 
used in this study. These are composed of LNA and 2’OMe, possess the same sequence and 162 
differ only in the internucleotide bonds. One possesses normal phosphodiester oligonucleotides 163 
(PO), while the other has one of the two non-bridging oxygen atoms replaced by a sulphur atom 164 
at each internucleotide linkage (PS) (Figure 1b). These oligonucleotides will be herein 165 
designated as PO and PS, respectively. The sequence of PO is 5’-166 
lGmeAmeClTmeAmeAlGmeCmeClC-3’, while the sequence of PS is 5’-167 
lG*meA*meC*lT*meA*meA*lG*meC*meC*lC*-3’, where “l” represents the LNA 168 
monomers, “me” the 2’OMe monomers and * the phosphorothioate linkages. These 169 
oligonucleotides were fluorescently labelled at 5’ with Cy3. They were synthetized and purified 170 
according to [49].  171 
 172 
Preparation of liposomes and lipoplexes and colloidal stability in simulated gastric 173 
juice 174 
Cationic liposomes composed of DOTAP and DOPE (in a 1:1 molar ratio) were prepared as 175 
reported before [59]. In brief, the lipids dissolved in chloroform were mixed and a dry lipid film 176 
was prepared by rotary evaporation of the chloroform at 40 ºC. The lipid film was hydrated 177 
with 20 mM HEPES buffer (pH 7.2) and sonicated using a probe sonicator (Branson Ultrasonics 178 
Digital Sonifier®, Danbury, USA), resulting in a final concentration of 5 mM DOTAP and 5 179 
mM DOPE. The average hydrodynamic size and zeta potential of the cationic liposomes was 180 
routinely checked by dynamic light scattering (Zetasizer Nano-ZS, Malvern, Worcestershire, 181 
UK).  182 
Lipoplexes were prepared through complexation of cationic liposomes with Cy3 labeled 183 
NAMs at a +/- charge ratio of 15; the +/- charge ratio is calculated as the molar amount of 184 
positive charges on the DOTAP molecules, divided by the molar amount of negative charges 185 
on the NAMs (with 1 NAM molecule containing 10 negatively charged phosphate groups). 186 
Complexation was performed by addition of a diluted dispersion of cationic liposomes to a 187 
NAM-solution (PS or PO), followed by incubation for 30 min, at room temperature.  188 
PEGylation of the thus obtained lipoplexes was performed by ‘post-insertion’ of  PEG lipids 189 
(2kDa CerC8-PEG or 2kDa DSPE-PEG) [60]. Therefore, the PEG lipids were first re-dissolved 190 
in sterile milli-Q water (after chloroform removal by nitrogen flush), added to the DOTAP-191 
DOPE-NAM complexes and incubated for 1h at 37 ºC. The PEG lipids accounted for 10% of 192 
the total lipids in the lipoplexes. The post-PEGylation efficacy was evaluated from the decrease 193 
in the (absolute) zeta potential value of the complexes, measured with the Zetasizer Nano-ZS. 194 
Throughout the paper, cationic lipoplexes are referred as Lpx, lipoplexes post-PEGylated with 195 
DSPE-PEG as DSPE Lpx, and lipoplexes post-PEGylated with Cer-PEG as Cer Lpx. 196 
Upon oral intake, the formulations will come in contact with the gastric juice. Therefore, we 197 
first tested if the liposomes are colloidally stable in simulated gastric juice (sGJ). The sGJ was 198 
prepared according to the US pharmacopeia: a solution of 0.2% (w/v) NaCl, 0.32% (w/v) gastric 199 
pepsin and 0.7% (v/v) HCl, final pH ≈ 1.2. The liposomes were diluted (10 times) in sGJ and 200 
incubated during 4 hours at 37 ˚C. Their hydrodynamic diameter was measured by dynamic 201 
light scattering.  202 
 203 
PEGylation of polystyrene nanospheres 204 
To assess the effect of the size of nanoparticles on their diffusion through gastric mucus 205 
isolated from pigs, polystyrene FluoSpheres® were PEGylated to render them muco-inert. 206 
Indeed, PEGylation may avoid the potential binding of the nanospheres to compounds present 207 
in mucus [20, 22].  208 
Yellow-green (505/515) fluorescent carboxylate-modified polystyrene FluoSpheres® of 40, 209 
100, 200 and 500 nm nominal diameter were covalently modified with PEG via amine coupling, 210 
as described elsewhere [50, 61]. In brief, mPEGa, EDC and sulfo-NHS were dissolved in 211 
HEPES Buffered Saline (HBS, pH 8). The nanospheres were added to this mixture so that a 212 
final concentration of 4 mg/mL EDC, 1.13 mg/mL sulfo-NHS, 10 mg/mL mPEGa and 1% 213 
solids (nanospheres) was obtained. The reaction mixture was left shaking overnight, at 200 rpm. 214 
Purification was then performed using a centrifugal filter (Amikon ultra centrifugal filters, 100 215 
K membrane, Millipore, MA, USA) for 12 min at 14,000 rpm, followed by two washings in 216 
HBS (12 min at 14,000 rpm). The filter was then placed upside down in a new vial and the 217 
purified PEGylated nanospheres were collected after centrifugation for 3 min at 1,000 rpm. 218 
They were resuspended in HBS to a final concentration of 2% solids (nanospheres) and stored 219 
at 4°C, until use. To allow optimal PEG coverage a slightly different protocol was used for the 220 
polystyrene nanospheres of 40 nm nominal diameter. The reaction mixture contained 0.5% 221 
solids (40 nm nanospheres) and it was left rotating for 5 days, at 30 rpm, using a Hulamixer 222 
(Life Technologies, Carlsbad, CA, USA). Purification was done by dialysis for 6h, employing 223 
a Slide-A-LyzerTM dialysis cassette with a 10 kDa molecular weight cut off (Thermo Scientific, 224 
Waltham, MA, USA), followed by ultracentrifugation (L8-70 M, Beckman, Coulter, Fullerton, 225 
CA, USA). The purified PEGylated 40 nm nanospheres were resuspended in HBS to a final 226 
concentration of 1% solids and stored at 4 °C. 227 
PEGylation of the polystyrene nanospheres was confirmed by measuring the zeta potential 228 
of the nanospheres in HEPES buffer, before and after reaction, using a Zetasizer Nano-ZS. 229 
		230 
Diffusion measurements of polystyrene nanospheres and lipoplexes in gastric mucus 231 
by single particle tracking (SPT) 232 
Diffusion measurements on the PEGylated polystyrene nanospheres and the (fluorescent) 233 
lipoplexes in mucus from the stomach of pigs were performed by fluorescence single particle 234 
tracking (SPT), at 37 °C, as described by our group elsewhere [50, 62]. For this, the PEGylated 235 
nanospheres were first sonicated for 5 min and diluted in sterile milli-Q water to a concentration 236 
suitable for SPT-measurements. Five µL of the diluted PEGylated nanospheres was gently 237 
mixed with ≈ 30 µL of mucus (taken with a plastic syringe, due to its high viscosity). This 238 
mixture was placed between a microscope slide and a coverslip with a double-sided silicon 239 
spacer of 1 mm thickness and 20 mm diameter in between (Press-to-seal silicone isolators; 240 
Molecular Probes, Leiden, The Netherlands). Measurements in sterile milli-Q water were 241 
performed as a control. For these, 7 µL of properly diluted PEGylated nanospheres was placed 242 
between a microscope slide and a coverslip with a double-sided adhesive spacer of 0.12 mm 243 
thickness and 9 mm diameter in between (Secure-Seal spacer; Molecular Probes, Leiden, The 244 
Netherlands). Before starting the SPT-measurements, the samples were equilibrated for 10 min 245 
at 37 °C in a stage-top incubator (Tokai Hit, Fujinomiya, Japan) mounted on the microscope.  246 
The diffusion measurements on the lipoplexes (Lpx, Cer Lpx and DSPE Lpx) were 247 
performed in the same way as described above for the PEGylated nanospheres. For these 248 
measurements, the liposomes were prepared to contain 1 mol% DOPE-LissamineRhodamineB 249 
for fluorescence imaging within the mucus.  250 
To study the diffusion of the fluorescent nanospheres and lipoplexes, typically 25 to 35 251 
‘SPT-movies’ were recorded at different locations in the mucus. Each SPT-movie was 5 s long 252 
and consisted of about 155 frames (recorded at a rate of 30.9 frames per second). The SPT-253 
measurements were done on a custom-built laser wide field microscope setup [50, 62]. The 254 
videos were analysed using an in-house developed software [63] to translate the nanoparticles 255 
trajectories into a distribution of apparent diffusion coefficients.  256 
 257 
Fluorescence in situ hybridization in H. pylori in suspension by free NAMs and 258 
lipoplexes  259 
H. pylori 26695 (ATCC 700392) was grown in trypticase soy agar supplemented with 5% 260 
sheep blood (Becton Dickinson GmbH, Germany) for 48 hours, at 37 °C, under microaerobic 261 
conditions. The bacteria were then harvested from the agar plates, using sterile saline solution, 262 
and diluted to nearly 2x108 cells/mL. The FISH procedure was based on a previously reported 263 
protocol [64], with some modifications. The bacteria in suspension were either treated with 264 
ethanol or mixed directly with the lipoplexes.  265 
For FISH experiments by ethanol based permeabilization of the bacteria, 100 µL of the 266 
bacterial suspension was pelleted by centrifugation for 15 min at 10,000 x g and resuspended 267 
in 500 µL of 50% (v/v) ethanol, for 15 min. Large H. pylori aggregates were removed by 268 
filtration through a sterile 10 μm pore size filter (CellTrics®, Görliz, Germany). 100 µL of the 269 
ethanol treated bacteria was then resuspended in 100 µL of hybridization solution (900 mM 270 
NaCl, 500 mM Urea, 50 mM Tris-HCl, pH 7) containing 400 nM of Cy3 labelled NAM PS or 271 
PO. 272 
For FISH experiments using lipoplexes, 100 µL of the initial bacterial suspension (diluted 273 
to a similar concentration as described above for the ethanol treatment) was resuspended in 100 274 
µL of hybridization solution containing lipoplexes (Lpx, Cer Lpx or DSPE Lpx) instead of free 275 
NAM. The amount of lipoplexes added was such that 400 nM of NAM PS or PO was present 276 
in the hybridization mixture. To be able to take into account the auto-fluorescence of H. pylori, 277 
negative control experiments were performed on bacteria resuspended in hybridization solution 278 
without NAM, for the conditions tested (with/without ethanol permeabilization and liposomes). 279 
As all negative controls looked the same, we only present example images of bacteria without 280 
exposure to ethanol nor liposomes. Hybridization was then performed by incubating the sample 281 
at 37 °C, for 30 min. Hybridization was followed by a washing step. For this, the bacteria were 282 
pelleted by centrifugation at 10,000 x g for 5 min, and resuspended in 500 µL of pre-warmed 283 
(37 °C) aqueous solution at pH 7. Instead, some samples were resuspended in 500 µL of a 0.1% 284 
(v/v) Triton X-100 solution to remove lipoplexes that remain bound to the bacterial outer 285 
membrane. The samples were then incubated at 37 °C, for 15 min. After washing, the bacteria 286 
were centrifuged at 10,000 x g for 5 min and resuspended in sterile milli-Q water. 20 µL of 287 
bacterial suspension was placed on a diagnostic slide (Thermo Scientific, Waltham, MA, USA) 288 
and allowed to dry at 37 °C.  289 
The slides were mounted with immersion oil and a coverslip and visualised under the 290 
microscope. Microscopy images were acquired using a Nikon TE2000 microscope equipped 291 
with a Nikon DS-Qi 1Mc digital camera and a Plan Apo VC 100× 1.4 NA oil immersion 292 
objective lens (Nikon). Cy3 fluorescence was visualized using a TRITC filter (excitation: 530-293 
560 nm; emission: 590-650 nm, Nikon). For fluorescence quantification, all samples were 294 
analysed using the same exposure time and the same excitation intensity; around 10 images per 295 
slide well were taken at different locations of the well.  296 
 297 
Fluorescence in situ hybridization in H. pylori by free NAMs and DSPE Lpx exposed 298 
to gastric mucus 299 
 The hybridization efficiency of free NAMs and DSPE Lpx (being the Lpx which transfected 300 
H. pylori in suspension the most successfully, see above), mixed with porcine gastric mucus 301 
was subsequently tested. As this required the application of mucus on top of the bacteria, it was 302 
not feasible to perform FISH on bacteria in suspension; instead FISH was performed on bacteria 303 
applied on glass slides, following the method we reported before [24]. Briefly, H. pylori in the 304 
exponential growth phase was harvested from the agar plates, using sterile saline solution, and 305 
diluted to nearly 1.6x106 cells/mL. Smears were prepared on glass slides (20 µL per slide well) 306 
by drying at 37 °C. To avoid cytotoxic effects of porcine mucus, as reported by others [65], the 307 
bacterial cells were fixed before contact with the mucus by incubation with 40 µL of 4% (w/v) 308 
paraformaldehyde, for 10 min. The free NAMs or the DSPE Lpx were 10x diluted in 309 
hybridization solution. 20 µL of these samples was added to approximately 30 µL of mucus 310 
and gently mixed. The final concentration of NAMs (whether free or in lipoplexes) within this 311 
mucus mixture was 400 nM (as is the case in the FISH experiments described above on FISH 312 
in suspension). The bacteria smear on the glass slide was covered by the mucus mixture and 313 
closed by a coverslip. The slide was placed in a dark moist chamber, hybridization was allowed 314 
for 30 min, at 37 °C. After hybridization the coverslip was removed together with the mucus 315 
mixture and the slide was washed during 15 min, 37 °C, in pre-warmed aqueous solution, at pH 316 
7. The slide was allowed to dry and fluorescence quantification was done as described above. 317 
To be able to take into account the auto-fluorescence of H. pylori, negative controls were 318 
performed using hybridization solution without free NAMs nor lipoplexes. 319 
 320 
Quantification of H. pylori hybridization 321 
For both hybridization with and without mucus the quantification was based on fluorescence 322 
microscopy and image processing, so that a reliable comparison could be done between all 323 
conditions; flow cytometry quantification would not be an option since it is not applicable to 324 
hybridization with mucus. 325 
The fluorescence of the bacteria obtained in the FISH experiments was quantified using an 326 
in-house developed software based on image processing routines available in Matlab (The 327 
MathWorks, Natick, MA, USA). First, bacteria were identified in each image based on an 328 
automatically determined intensity threshold. This results in a binary mask that corresponds to 329 
the location of bacteria in the image. For the regions within the mask, the average fluorescence 330 
intensity in the original image (ܨ௜௠௔௚௘) was quantified as: 331 
ܨ௜௠௔௚௘ ൌ ∑ ሾሺ ௕݂െܤܩ௕ሻ ൈ #݌݅ݔ௕ሿ
௡௕ୀଵ
∑ #݌݅ݔ௕௡௕ୀଵ 	, 332 
where ܾ refers to each bacterium, ݊ corresponds to the number of bacteria in the image, ௕݂ 333 
corresponds to the mean pixel fluorescence of each bacterium, ܤܩ௕ is the local background 334 
value around each bacterium and #݌݅ݔ௕ is the number of pixels comprising each bacterium. 335 
Per sample, around 10 images were analysed in this fashion. Three repeated samples were 336 
analysed per treatment, from which the average fluorescence intensity was calculated. These 337 
absolute values were normalized to the respective positive control of PS or PO. Three 338 
independent experiments were performed and the average normalized fluorescence from the 3 339 
treatment replicates was finally obtained.  340 
 341 
Statistical analysis 342 
Statistical analysis was performed by GraphPad Prism6 software (GraphPad Software, San 343 
Diego, USA). The FISH results were analysed using two-way analysis of variance (ANOVA) 344 
and Sidak’s multiple comparison test, comparing the samples with the respective reference 345 
(fluorescence 1) within the same NAM. Fluorescence 1 corresponds to ETH+NAM (Figure 3 346 
and 5), or NAM (Figure 6). Significance was set at P ≤ 0.05 (**** P ≤ 0.0001, *** P ≤ 0.001, 347 
** P ≤ 0.01, * P ≤ 0.05).  348 
 349 
 350 
Results 351 
Characterization of the liposomes and lipoplexes  352 
Cationic liposomes were prepared from DOTAP and DOPE, in a 1:1 molar ratio, following 353 
the lipid film hydration method [59]. The liposomes had an average hydrodynamic diameter of 354 
around 80-100 nm and an average zeta potential about +40-55 mV. Cationic lipoplexes were 355 
prepared by incubation of DOTAP-DOPE liposomes with NAM PS or PO. The cationic 356 
lipoplexes (Lpx) were subsequently post-PEGylated with Cer-PEG (Cer Lpx) or DSPE-PEG 357 
(DSPE Lpx). Both types of PEG chains were successfully inserted into the complexes, as was 358 
observed from the decrease in zeta potential of the lipoplexes (Figure S1a). In all cases the final 359 
zeta potential of the PEGylated lipoplexes was around 15 mV, with an average hydrodynamic 360 
diameter ranging from 98 nm to 133 nm (Figure S1a). Upon oral intake, liposomes will come 361 
into contact with the gastric juice. We, therefore, tested the colloidal stability of the liposomes 362 
(both for non-PEGylated and PEGylated liposomes) in simulated gastric juice, and found that 363 
their size remains constant for at least 4h (Figure S2a). Together with the chemical stability of 364 
free NAMs under gastric pH [64], it is a strong indication that the gastric juice will not impose 365 
a constraint in a clinical application. 366 
 367 
Diffusion measurements of polystyrene nanospheres and lipoplexes in gastric mucus 368 
by single particle tracking (SPT) 369 
As gastric mucus represents a challenging diffusional barrier, we first evaluated how the size 370 
of nanoparticles influences their mobility in gastric mucus. To that end, the diffusion of model 371 
nanospheres of defined sizes was assessed. We noticed that the nanospheres of 40 nm nominal 372 
size were actually bigger with a hydrodynamic radius of approximately 60 nm, as measured by 373 
dynamic light scattering (Figure S1b); therefore, in our results we refer to them as ’60 nm’ 374 
nanospheres (instead of ’40 nm’). The nanospheres were first PEGylated to avoid muco-375 
adhesion [21, 50]. The PEG could be conjugated to the polystyrene nanospheres, as judged 376 
from the clear zeta potential change towards neutral values (Figure S1b).  377 
As expected, due to the size-filtering effect of mucus [19], the larger the PEGylated 378 
nanospheres, the lower their diffusional mobility in gastric mucus, as measured by SPT (Figure 379 
2a and Table S1; example movies 1-4 in supplementary material). Both 60 and 100 nm 380 
nanospheres showed a bimodal distribution of diffusion coefficients, indicating that a part of 381 
those particles is mobile while another fraction is immobilized. The mobile fraction was clearly 382 
smaller for the 200 nm nanospheres and almost non-existing for the 500 nm particles. This 383 
shows that the mesh size of gastric mucus is quite heterogeneous, as already observed before 384 
for gastrointestinal mucus [18, 19]. Other types of mucus do not seem to show such high level 385 
of heterogenicity; for instance in cystic fibrosis sputum PEGylated nanospheres of 100 nm and 386 
200 nm (similar to the ones used here) showed good and uniform mobility with an unimodal 387 
distribution of diffusion coefficients [50]. Our diffusion results in gastric mucus indicate that 388 
nanoparticles should preferably be as small as possible for efficient diffusion in gastric mucus, 389 
and in any case they should be smaller than 200 nm.  390 
While the lipoplexes under investigation do fulfil this criterion, their diffusion in porcine 391 
gastric mucus was experimentally verified by SPT as well (example PS movies 5-7 in mucus 392 
and movies 8-10 in water in supplementary material). Figure 2b show that non-PEGylated Lpx 393 
(Lpx) clearly had the lowest mobility, as could be expected due to interactions with mucus 394 
constituents. Post-PEGylation (Cer Lpx and DSPE Lpx) increases the mobile fraction slightly, 395 
resulting in a 3 to 5-fold higher average diffusion coefficient (Table S1). Nevertheless, the 396 
improvement of the diffusion by PEGylation is rather moderate and a substantial non-mobile 397 
fraction remains present. It confirms that nanoparticle size poses a serious limitation to diffusion 398 
in the dense gastric mucus.  399 
In our previous study it was found that the type of internucleotide linkage (PS or PO) affected 400 
the diffusion and interaction with mucus [24]. In particular, the PS modification (generally used 401 
to increase oligonucleotides stability against nucleases and affinity towards the target sequence 402 
[66]) led to slower diffusion and increased interaction with mucus components. The current 403 
results show that the use of liposomes as carriers for the NAMs removes these differences as 404 
they diffuse at a similar rate irrespective of the type of NAM used.  405 
 406 
 407 
Figure 2. Distribution of diffusion coefficients of polystyrene nanospheres and lipoplexes in 408 
gastric mucus isolated from pigs. Results obtained on gastric mucus from 3 different porcine 409 
mucus samples were pooled. (a) PEGylated nanospheres of around 60 nm (PEG 60 nm), 100 410 
nm (PEG 100 nm), 200 nm (PEG 200 nm) and 500 nm (PEG 500 nm) in diameter. (b) Cationic 411 
lipoplexes (Lpx) compared with Cer Lpx and DSPE Lpx. The dotted line shows the diffusion 412 
of Lpx in water.  413 
 414 
Fluorescence in situ hybridization in H. pylori in suspension by free NAMs and 415 
lipoplexes   416 
After crossing the gastric mucus, lipoplexes should be able to deliver the NAMs across the 417 
cell envelope (Figure 1a). To test this, we first compared the hybridization efficiency of 418 
lipoplexes in a suspension of H. pylori to the ‘standard procedure’ involving ethanol mediated 419 
membrane permeabilization [64]. As presented in Figure 3, similar results were found for PO 420 
and PS NAMs. Free NAMs are only slightly taken up by untreated cells, which increases 2-3 421 
fold upon permeabilization of the bacteria with ethanol. Interestingly, Lpx and Cer Lpx 422 
performed equally well as the standard ethanol treatment. The lipoplexes functionalized with 423 
DSPE-PEG performed even better, with a 4-fold higher hybridization efficiency as compared 424 
to ethanol treatment. Based on our transfection experience with eukaryotic cells it was rather 425 
unexpected that non-PEGylated Lpx did not have the best performance, since PEGylation 426 
typically reduces the interactions with the cell membrane [67, 68]. We reckon that this is due 427 
to the extensive aggregation of non-PEGylated Lpx in the hybridization solution (Figure S2b), 428 
which likely reduces the liposomal interaction with the bacterial envelope. PEGylated Lpx, on 429 
the other hand, showed excellent colloidal stability in the hybridization solution (Figure S2b). 430 
This improved stability did not prevent effective lipoplexes interactions with H. pylori 431 
membrane (as shown in Figure 3). This is in line with previous reports on antimicrobials 432 
delivery into bacteria by PEGylated liposomes [69, 70] which were shown to interact with 433 
bacterial cell membranes [71].  434 
 435 
Figure 3. FISH in H. pylori in suspension. The hybridization efficiency of Lpx, Cer Lpx and 436 
DSPE Lpx was compared with the hybridization efficiencies observed with free NAMs in H. 437 
pylori respectively not treated (NAM) and pre-treated with ethanol (ETH+NAM), for both PS 438 
and PO. Negative controls without NAM (neg) were also included. (a) Representative 439 
epifluorescence microscopy images, all taken with the same exposure time. (b) FISH 440 
fluorescence normalized to that of free NAM in ethanol permeabilized H. pylori (ETH+NAM). 441 
Within one experiment, each condition was performed in triplicate. Three independent 442 
experiments were performed. Results are presented as mean values and respective standard 443 
deviation.  444 
 445 
Confirmation of the intracellular delivery of NAMs in H. pylori by DSPE Lpx  446 
The FISH results as presented in Figure 3 are obtained by fluorescence microscopy. It is to 447 
be noted, however, that the width of the bacteria is only 0.5-1 µm, which is rather close to the 448 
optical resolution limit (~ 0.25 µm). As such, we wanted to confirm that the fluorescence of the 449 
bacteria is coming from intracellular NAMs and not just from DSPE Lpx that remain attached 450 
to the outer surface of the bacteria. To this end, DSPE Lpx were applied to H. salomonis, a 451 
morphologically similar Helicobacter to which the NAMs should not hybridize [49, 64]. 452 
Interestingly, for both PS and PO, DSPE Lpx appeared as fluorescent halos around H. 453 
salomonis cells, with no fluorescence in the cytosol (Figure 4). This is in stark contrast with the 454 
uniform fluorescence that is observed throughout the H. pylori cells (Figure 4). This confirms 455 
that the observed fluorescence in H. pylori at least in part stems from intracellular NAMs 456 
retained by hybridization with the target rRNA.  457 
 458 
 459 
Figure 4. FISH using DSPE Lpx PS and DSPE Lpx PO, respectively, in H. pylori and H. 460 
salomonis. Uniform fluorescence is seen in H. pylori, while H. salomonis shows a hollow 461 
interior with an extracellular fluorescent halo. 462 
 463 
It cannot be excluded, however, that part of the observed fluorescence in H. pylori results 464 
from remaining membrane-bound DSPE Lpx. To find this out, a mild triton wash was 465 
performed after hybridization. The samples were washed with a 0.1% (v/v) Triton X-100 466 
solution (instead of the regular washing solution), to remove any remaining lipoplexes that are 467 
bound to the outer bacterial membrane. As expected, the extracellular fluorescent halos in H. 468 
salomonis could be almost completely removed by the triton wash (Figure S3), which 469 
demonstrates that this protocol works as intended. When applied to H. pylori, the triton did 470 
lower the observed fluorescence intensity, leaving only the fluorescence coming from the 471 
intracellular NAMs (Figure 5). For PS NAMs, the remaining fluorescence was at the same level 472 
as for ethanol permeabilized cells treated with free NAMs. For PO NAMs, the fluorescence 473 
remained about 3-fold higher. The reason for this difference is not clear. In conclusion, although 474 
a part of the DSPE Lpx PS fluorescence in H. pylori did come from membrane bound 475 
lipoplexes, these results give clear evidence that NAMs were successfully delivered inside H. 476 
pylori to an extent that is at least as good as the standard in vitro ethanol permeabilization 477 
method. 478 
 479 
 480 
Figure 5. Discrimination between extracellular adhesion and intracellular delivery of NAMs 481 
into H. pylori cells by lipoplexes. The H. pylori fluorescence obtained upon regular wash 482 
(representing the total, i.e. intra- plus extracellular, fluorescence) was compared with the one 483 
obtained upon mild triton wash (representing the intracellular fluorescence). DSPE Lpx were 484 
compared with free NAMs in ethanol treated bacteria (ETH+NAM). Negative controls without 485 
NAMs (neg) were also included. (a) Representative epifluorescence microscopy images (all 486 
taken with the same exposure time). (b) FISH fluorescence normalized to that of free NAMs in 487 
ethanol treated (ETH+NAM) H. pylori. Within one experiment, each condition was performed 488 
in triplicate. Three independent experiments were performed. Results are presented as mean 489 
values and respective standard deviation.  490 
 491 
Fluorescence in situ hybridization in H. pylori by free NAMs and DSPE Lpx exposed 492 
to gastric mucus 493 
We showed above that DSPE Lpx can successfully deliver NAMs in H. pylori in suspension 494 
(Figure 4 and 5) while at least a fraction of DSPE Lpx is mobile in gastric mucus isolated from 495 
pigs (Figure 2b). In a next step, we investigated whether hybridization in H. pylori by DSPE 496 
Lpx is still successful in the presence of gastric mucus. To this end, free NAMs or DSPE Lpx 497 
dispersed in hybridization solution were mixed with porcine gastric mucus (in a 2:3 ratio) and 498 
applied on top of an H. pylori bacterial smear on a glass slide. After incubation for 30 min, the 499 
mucus mixture was removed, the slide was washed (regular wash) and cells were imaged by 500 
fluorescence microscopy. Compared to free NAMs, the DSPE Lpx show a 2-2.7 fold increase 501 
in fluorescence intensity of H. pylori, both for PO and PS NAMs (Figure 6). The question again 502 
comes if perhaps part of this fluorescence is coming from membrane bound lipoplexes. When 503 
the same experiments were performed with H. salomonis, the outer fluorescent rim, as observed 504 
in solution, was no longer present (Figure S4). This suggests that excessive sticking of 505 
lipoplexes to the outer cell envelope does not happen in the presence of mucus, so that the 506 
observed fluorescence in H. pylori (Figure 6a and 6b) can be ascribed to intracellularly 507 
delivered and hybridized NAMs. Taken together we conclude that DSPE Lpx (both PS and PO) 508 
have the capacity to deliver NAMs into H. pylori even in the presence of the tough gastric 509 
mucus barrier.  510 
 511 
 512 
Figure 6. FISH in H. pylori (on a glass slide) by free NAMs and DSPE Lpx exposed to gastric 513 
mucus isolated from pigs. Note that there was no pre-treatment of the bacteria with ethanol. 514 
Negative controls without NAMs (neg) were also included. (a) Representative epifluorescence 515 
microscopy images, all taken with the same exposure time. (b) FISH fluorescence normalized 516 
to that of free NAMs. Within one experiment, each condition was performed in triplicate. 517 
Independent experiments were done using mucus from 3 different pigs. Results are presented 518 
as mean values and respective standard deviation.  519 
 520 
 521 
Discussion  522 
For NAMs to become a novel platform to target infections in vivo for diagnosis and therapy, 523 
they have to cross biological barriers, like the bacterial cell envelope and the mucus that covers 524 
the epithelia, in order to reach their intracellular bacterial targets without loss of activity [23, 525 
72]. We investigated whether liposomes, composed of the cationic lipid DOTAP and the neutral 526 
fusogenic lipid DOPE, would be suitable nanocarriers for delivering NAMs across the gastric 527 
mucus barrier in H. pylori cells. We compared cationic and post-PEGylated lipoplexes, 528 
anticipating the need of PEG stabilization to safely cross the harsh gastric environment. Based 529 
on previous experiments with mammalian cells, PEGylation typically comes at the price of 530 
reduced cell interactions. Therefore, two different PEGs were tested: DSPE-PEG, which stably 531 
incorporates into liposomes, and Cer-PEG, which can diffuse out of the liposomes over time 532 
[52, 53]. 533 
Before reaching H. pylori in the stomach, lipoplexes will encounter the gastric mucus (Figure 534 
1a) which is a tough barrier that limits the diffusion of nanoparticles and molecules [18]. 535 
Recently we showed that, while gastric mucus does not hinder the diffusion of the small sized 536 
NAMs, binding of mucus components to NAMs does happen which hampers efficient 537 
hybridization in H. pylori [24]. We reasoned that a nanocarrier that (i) shields NAMs from such 538 
interactions and (ii) can penetrate into the mucus where bacteria reside could be valuable [23, 539 
55]. Nanoparticle diffusion through mucus is determined both by their size and surface 540 
properties [73]. PEGylation is the commonly employed strategy to limit the adhesive 541 
interactions of nanoparticles with mucus [39, 51]. Furthermore, PEGylation may offer 542 
additional protection to the NAMs bound at the surface of liposomes by providing a steric 543 
barrier against muco-interactions. As the size of the pores in human gastric mucus is still not 544 
well characterized [20] we first studied the diffusion of PEGylated nanospheres, varying in size, 545 
in mucus isolated from the stomach of pigs. It is of note that porcine gastric mucus is considered 546 
to better resemble human mucus than gastric murine or rabbit mucus [57]. Our results suggest 547 
that nanoparticles should be smaller than 200 nm to maintain a mobile fraction in gastric mucus 548 
(Figure 2a). Although similar diffusion studies in porcine gastric mucus have not yet been 549 
performed to our knowledge, our observations are in line with studies in gastrointestinal mucus. 550 
For instance in intestinal mucus, using porcine and murine models, it was also reported that 551 
PEGylated 500 nm nanospheres were hindered, while PEGylated 200 nm nanospheres were 552 
able to penetrate murine small intestinal mucus, but not colonic mucus [20, 74]. This is further 553 
supported by the observation that PEGylated 200 and 500 nm nanoparticles distributed 554 
throughout the colorectal epithelium of mice in vivo less uniformly than PEGylated 100 and 40 555 
nm nanospheres [22].  556 
Moving on to the diffusion of NAM lipoplexes, we found that PEGylation did improve 557 
mobility, although a fraction of the lipoplexes remained immobilized (Figure 2b). This fraction 558 
appeared to be higher than for PEGylated nanospheres of similar size (Figure 2a). Although 559 
both lipoplexes and nanospheres have a PEGylated surface and thus a substantially reduced 560 
surface charge, compared to nanospheres the lipoplexes possess a slightly higher and net 561 
positive charge. This may contribute to increased binding, and hence slower diffusion in mucus, 562 
as also reported for other cationic nanoparticles in other types of mucus [50, 62, 75].  563 
In future work one could consider developing even smaller nanocarriers, such as micelles or 564 
self-nanoemulsifying drug delivery systems (SNEDDS) to further improve diffusion in dense 565 
gastric mucus [76, 77]. Also, it could be attractive to focus on smaller liposomes which could 566 
be prepared by microfluidic mixing [78, 79]. DOTAP-DOPE liposomes of 50 to 75 nm could 567 
be reproducibly manufactured in this way [80]. An alternative to enhance diffusion through 568 
gastric mucus could be the use of mucolytics. However, the effect of mucolytic agents like N-569 
acetyl-L-cysteine on nanoparticle penetration through mucus is not always clear, while it can 570 
irreversibly compromise the functionality of mucus as a defensive barrier against pathogens 571 
[76, 81, 82].  572 
Next, we evaluated if (PEGylated) Lpx have the potential to deliver NAMs across the cell 573 
envelope and into the cytoplasm of H. pylori cells. The envelope of gram negative bacteria, 574 
composed of a cytoplasmic membrane, periplasm, peptidoglycan layer and an outer membrane 575 
[83], is repeatedly reported as a hurdle for oligonucleotide penetration in different bacteria [9, 576 
84, 85]. It is believed that oligonucleotides are too large to passively diffuse through the 577 
bacterial envelope [8]. The traditional method, therefore, to deliver NAMs in gram negative 578 
bacteria in vitro involves membrane permeabilization with ethanol [64]. Clearly, ethanol 579 
mediated permeabilization is not transferable to in vivo conditions which necessitates other 580 
methods for the delivery of NAMs into bacterial cells. In this study we evaluated if fusogenic 581 
DOTAP-DOPE liposomes could be suitable nanocarriers. As the fluorescent NAMs in the 582 
hybridization solution were designed to specifically hybridize in H. pylori [49], FISH could be 583 
used to evaluate successful intracellular delivery. We found that while the cationic and Cer Lpx 584 
hybridization performance was nearly similar to free NAMs in ethanol treated cells, DSPE Lpx 585 
performed even markedly better (Figure 3). After removing extracellular membrane bound 586 
DSPE Lpx, still a 1-3 fold increase in hybridization efficiency was retained as compared to the 587 
standard ethanol protocol (Figure 5). This demonstrates the capacity of DSPE Lpx to 588 
successfully deliver NAMs in the cytosol of H. pylori. 589 
Having found that DSPE Lpx have partial mobility in gastric mucus and can deliver NAMs 590 
in the cytosol of H. pylori, we finally tested the hybridization efficacy of DSPE Lpx in the 591 
presence of gastric mucus. A more than 2 fold improvement in hybridization efficiency was 592 
found with DSPE Lpx when compared to free NAMs (Figure 6). This enhancement shows the 593 
ability of DSPE Lpx to protect NAMs from interacting with mucus constituents, thus retaining 594 
their hybridization activity. We noticed that the remaining adhesion of DSPE Lpx to the 595 
bacterial outer membrane, as observed in solution, was almost entirely invisible in the presence 596 
of mucus. This may be due to the presence of mucins that compete with lipoplexes for 597 
interaction with the bacterial envelope, thereby reducing the sticking of DSPE Lpx to the outer 598 
membrane [86, 87]. When the aim is to specifically detect H. pylori by FISH in a diagnostic 599 
setting, this could be an advantage as it may avoid unspecific fluorescence due to the binding 600 
of the DSPE Lpx to non-target bacteria. However, when the aim is to treat the infection, one 601 
could argue that reduced interaction with the cell envelope may reduce the delivery efficiency. 602 
In that sense active targeting of the lipoplexes towards H. pylori membranes, e.g. by conjugation 603 
of mannose-specific or fucose-specific lectins [88, 89], could be evaluated to improve 604 
interactions with the bacterial cell envelope and increase the intracellular delivery efficiency.  605 
Based on our encouraging in vitro results, future investigation should focus on the in vivo 606 
performance of DSPE Lpx PS and PO. The necessary dose to diagnose/treat the infection needs 607 
to be investigated, considering the potential dose dependent toxicity to the animal. For the 608 
diagnosis of the H. pylori infection, the in vivo detection of the fluorescence signal, its 609 
sensitivity and specificity need to be considered. Detection in the stomach could be performed 610 
using an existing confocal endomicroscopy probe [90, 91]. Although accessibility may be a 611 
limitation, we believe a porcine model would be the indicated in vivo model, as it resembles the 612 
human gastric environment and mucus barrier much better than mice models [56, 57]. 613 
Moreover, it would be feasible for the detection by the endomicroscope probe, as the small size 614 
of mice may limit a proper assessment of the endomicroscopy’s capability to visualize the 615 
fluorescence signal in the animal stomach. 616 
 617 
Conclusions 618 
This study shows, for the first time, successful delivery of NAMs into bacterial cells by 619 
DSPE-PEGylated liposomes in which also the mucus associated to the bacterial infection is 620 
considered as a potential barrier. It shows that such PEGylated liposomes represent a valuable 621 
opportunity in the post-antibiotic era to deliver NAMs as a novel class of therapeutic 622 
antimicrobials and diagnostic agents. Future research will focus on evaluating DSPE Lpx in 623 
other important pathogens, developing smaller carriers to further improve the diffusion of the 624 
carriers in mucus and testing their in vivo performance. 625 
 626 
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